Cantor Fitzgerald Forecasts AVITA Medical FY2025 Earnings

AVITA Medical, Inc. (NASDAQ:RCEL) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of AVITA Medical in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn anticipates that the company will post earnings per share of ($1.14) for the year. Cantor Fitzgerald has a “Overweight” rating and a $21.00 price objective on the stock. The consensus estimate for AVITA Medical’s current full-year earnings is ($2.35) per share.

Several other analysts have also recently weighed in on the stock. Lake Street Capital decreased their price objective on shares of AVITA Medical from $20.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Piper Sandler reissued a “neutral” rating and issued a $12.00 price target (up previously from $9.00) on shares of AVITA Medical in a research note on Friday, November 8th. Finally, D. Boral Capital reissued a “buy” rating and issued a $25.00 price target on shares of AVITA Medical in a report on Wednesday, January 8th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, AVITA Medical currently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

AVITA Medical Stock Performance

Shares of NASDAQ RCEL opened at $8.73 on Wednesday. The business has a fifty day simple moving average of $12.03 and a 200 day simple moving average of $10.67. The firm has a market capitalization of $228.88 million, a price-to-earnings ratio of -3.91 and a beta of 1.58. AVITA Medical has a one year low of $7.51 and a one year high of $18.93. The company has a current ratio of 3.73, a quick ratio of 3.37 and a debt-to-equity ratio of 3.48.

AVITA Medical (NASDAQ:RCEL) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.21). AVITA Medical had a negative return on equity of 194.69% and a negative net margin of 95.47%. The business had revenue of $19.55 million for the quarter, compared to analyst estimates of $19.65 million. During the same quarter last year, the company earned ($0.34) EPS.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of RCEL. Geode Capital Management LLC boosted its position in shares of AVITA Medical by 1.4% during the 3rd quarter. Geode Capital Management LLC now owns 594,436 shares of the company’s stock worth $6,373,000 after purchasing an additional 8,361 shares in the last quarter. State Street Corp raised its stake in shares of AVITA Medical by 2.4% during the 3rd quarter. State Street Corp now owns 519,997 shares of the company’s stock worth $5,574,000 after purchasing an additional 11,997 shares during the period. Essex Investment Management Co. LLC bought a new position in shares of AVITA Medical during the 3rd quarter valued at approximately $2,477,000. Jane Street Group LLC increased its holdings in AVITA Medical by 32.7% in the 3rd quarter. Jane Street Group LLC now owns 89,395 shares of the company’s stock worth $958,000 after acquiring an additional 22,032 shares during the last quarter. Finally, Barclays PLC grew its stake in AVITA Medical by 340.0% in the 3rd quarter. Barclays PLC now owns 37,503 shares of the company’s stock valued at $402,000 after buying an additional 28,979 shares in the last quarter. Institutional investors own 27.66% of the company’s stock.

AVITA Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.